News
Anteris Technologies Global
AVR · NASDAQ
$6.29+$0.11 (+1.78%)TodayMarket closed ·
Prev close $6.18
Latest news
- Press releaseGlobe Newswire
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
- Press releaseGlobe Newswire
Anteris Technologies Announces Results for the Second Quarter of 2026
- News
Anteris Technologies Receives Full Regulatory Clearance From The French National Agency For Medicines And Health Products Safety For The DurAVR Transcatheter Heart Valve Global Pivotal Trial In Patients With Severe Calcific Aortic Stenosis
- Press releaseGlobe Newswire
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
- Press releaseGlobe Newswire
Anteris Announces Results for the First Quarter of 2026
- Press releaseGlobe Newswire
Anteris Reports 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
- NewsAvi Kapoor
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Anteris Announces Results for the Third Quarter of 2025
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
Anteris Technologies Receives Danish Regulatory Clearance To Launch Global PARADIGM Trial For DurAVR Heart Valve
- NewsAvi Kapoor
Top 2 Health Care Stocks That May Keep You Up At Night This Month
- Press releaseBusiness Wire
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.